Literature DB >> 25205902

Desferioximine induced Ototoxicity in Thalassemic patients.

Dharam Vir1, N K Panda2, R K Marwaha3.   

Abstract

BACKGROUND: Thalassemia is a hereditary disorder requiring regular blood transfusion.
PURPOSE: To determine hearing sensitivity in transfusion-dependent thalassemics who were receiving desferioximine and on oral iron chelation (desferioximine) therapy.
METHODS: 26 patients with B-thelassemia in the age range of 5-22 years were enrolled in the thalassemia transfusion unit in the Advanced Pediatric Center of Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. The patients to be enrolled in this study were randomly selected.
RESULTS: It was observed that the hearing deteriorated in patients who were given injected desferioximine whereas it fell within normal limits in case of those who were given oral iron chelation therapy. CONCLUSON: This study confirms the necessity of regular audiological monitoring during the course of the disease.

Entities:  

Keywords:  Desferioximine; Injection therapy; Oral therapy; Thalassemia

Year:  2010        PMID: 25205902      PMCID: PMC4117009          DOI: 10.5214/ans.0972.7531.1017407

Source DB:  PubMed          Journal:  Ann Neurosci        ISSN: 0972-7531


  16 in total

1.  Iron excretion in thalassaemia major after administration of chelating agents.

Authors:  R S SMITH
Journal:  Br Med J       Date:  1962-12-15

2.  Arterial obstruction of the labyrinth. I. Cochlear changes.

Authors:  R KIMURA; H B PERLMAN
Journal:  Ann Otol Rhinol Laryngol       Date:  1958-03       Impact factor: 1.547

3.  Postmortem changes in surface preparations of the cochlea.

Authors:  V M Jordan; K Chiba; M L Pinheiro; A Jimenez
Journal:  Ann Otol Rhinol Laryngol       Date:  1973 Jan-Feb       Impact factor: 1.547

4.  Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.

Authors:  G M Brittenham; P M Griffith; A W Nienhuis; C E McLaren; N S Young; E E Tucker; C J Allen; D E Farrell; J W Harris
Journal:  N Engl J Med       Date:  1994-09-01       Impact factor: 91.245

5.  Survival and desferrioxamine in thalassaemia major.

Authors:  B Modell; E A Letsky; D M Flynn; R Peto; D J Weatherall
Journal:  Br Med J (Clin Res Ed)       Date:  1982-04-10

6.  Vision and hearing during deferoxamine therapy.

Authors:  A Cohen; M Martin; J Mizanin; D F Konkle; E Schwartz
Journal:  J Pediatr       Date:  1990-08       Impact factor: 4.406

7.  Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.

Authors:  L Wolfe; N Olivieri; D Sallan; S Colan; V Rose; R Propper; M H Freedman; D G Nathan
Journal:  N Engl J Med       Date:  1985-06-20       Impact factor: 91.245

8.  Deferoxamine-induced bone dysplasia in patients with thalassemia major.

Authors:  P W Brill; P Winchester; P J Giardina; S Cunningham-Rundles
Journal:  AJR Am J Roentgenol       Date:  1991-03       Impact factor: 3.959

9.  Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine.

Authors:  L A Styles; E P Vichinsky
Journal:  J Pediatr Hematol Oncol       Date:  1996-02       Impact factor: 1.289

10.  Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.

Authors:  N F Olivieri; J R Buncic; E Chew; T Gallant; R V Harrison; N Keenan; W Logan; D Mitchell; G Ricci; B Skarf
Journal:  N Engl J Med       Date:  1986-04-03       Impact factor: 91.245

View more
  2 in total

1.  Sensorineural Hearing Loss and Its Relationship with Duration of Chelation Among Major β-Thalassemia Patients.

Authors:  Muhammad Ali Khan; Mahrukh A Khan; Ahmed M Seedat; Maria Khan; Sana F Khuwaja; Ram Kumar; Syed Muhammad Usama; Sundus Fareed
Journal:  Cureus       Date:  2019-08-22

Review 2.  Hearing Loss in Beta-Thalassemia: Systematic Review.

Authors:  Immacolata Tartaglione; Roberta Carfora; Davide Brotto; Maria Rosaria Barillari; Giuseppe Costa; Silverio Perrotta; Renzo Manara
Journal:  J Clin Med       Date:  2021-12-25       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.